CD19 and neoplasm: In addition, the co-targeting of CD47 and CD19 enhances the expected safety, as well as induces antibody dependent cytotoxicity (ADCC) by retaining the function of its IgG1 Fc region, thereby providing a second mechanism for anti-tumor activity.